DS_10.1177_2381468318781811 – Supplemental material for The Lifetime Health Burden of Delayed Graft Function in Kidney Transplant Recipients in the United States

<p>Supplemental material, DS_10.1177_2381468318781811 for The Lifetime Health Burden of Delayed Graft Function in Kidney Transplant Recipients in the United States by Devin Incerti, Nicholas Summers, Thanh G. N. Ton, Audra Boscoe, Anil Chandraker and Warren Stevens in MDM Policy & Practice</p

Phenotypic composition of T lymphocytes in the BK negative, viruria, and viremia groups.

<p><b>2A: CD4+ T-Cell Phenotypes</b> *P < 0.05. “Pre-Tx” = Pre-transplant. “mo” = Months post-transplant. P values were calculated by Kruskall-Wallis comparing each T-cell subgroup at each time point. Effector Cells are CD45RO-/CD27-; Effector Memory Cells are CD45RO+/CD27-; Central Memory Cells are CD45RO+/CD27+; Naïve Cells are CD45RO-/CD27+. Expressed are means as a percent of total CD4+ T-Cells, may not add to 100% due to rounding. *Effector memory cells at 3 months in BK negative 15.93% (±11.29), viruria 20.00% (±12.00) and viremia 5.59% (±2.32) P = 0.05. <b>2B: CD8+ T-Cell Phenotypes</b> *P < 0.05. “Pre-Tx” = Pre-transplant. “mo” = Months post-transplant. P values were calculated by Kruskall-Wallis comparing each T-cell subgroup at each time point. Effector Cells are CD45RO-/CD27-; Effector Memory Cells are CD45RO+/CD27-; Central Memory Cells are CD45RO+/CD27+; Naïve Cells are CD45RO-/CD27+. Expressed are means as a percent of total CD8+ T-Cells, may not add to 100% due to rounding. *Baseline percent effector cells for viremia is 21.41% (±13.11), viruria 4.04% (±4.51) and BK negative is 5.49% (±4.76), P = 0.04. 12 month percent effector cells for viremia is 14.49% (±3.76), viruria 3.86% (±1.64), and BK negative 4.10% (±4.19), P = 0.01.</p

Univariable GEE logistic regression for BKPyV viremia.

<p>Univariable GEE logistic regression for BKPyV viremia.</p

Anti-BKPyV IgG.

<p>Line represents mean value. “OD” = Optical Density, “-” = BK Negative, “U” = viruria, “P” = viremia, “mo” = months post-transplant. “Pre-Tx” = Pre-transplant. P values were calculated by Kruskall-Wallis comparing all 3 groups at each time point. 12 month mean for BK negative 1.25 (± 0.70), viruria 2.03 (± 0.43), viremia 2.15(± 0.02), P = 0.02.</p

GEE logistic regression for BKPyV reactivation.

<p>GEE logistic regression for BKPyV reactivation.</p

Study subject characteristics.

<p>Study subject characteristics.</p

BKPyV specific (A) CD4⁺ and (B) CD8⁺ T-cells.

<p>Line represents mean value. “-” = BK Negative, “U” = viruria, “P” = viremia, “mo” = months post-transplant. “Pre-Tx” = Pre-transplant. P values were calculated by Kruskall-Wallis comparing all 3 groups at each time point. <b>A</b>: No significant difference at any time point. <b>B</b>: 3 month mean %IFN-γ producing CD8⁺ T-Cells for BK negative 1.29 (±2.36), viruria 1.54 (±1.21), viremia 6.67 ±0.54), P = 0.02; 6 months mean for BK negative 1.81 (±4.10), viruria 12.65 (±11.10) and viremia 17.22 (±18.68), P = 0.05; 12 months mean for BK negative 0.53 (±0.91), viruria 9.44 (±7.13), viremia 10.97 (±8.85), P = 0.01.</p

GEE Linear regression for change in variable per month post-transplant.

<p>GEE Linear regression for change in variable per month post-transplant.</p

Prevalence of BKPyV detected in the plasma or urine.

<p>Prevalence of BKPyV detected in the plasma or urine.</p

Sustained Virologic Response.

<p>Overall sustained virologic response, stratified by stage of fibrosis. The graph indicates the number of patient who achieved undetectable HCV viral load at 12 weeks post-treatment. Of note, one patient had a negative HCV viral load measured at week 4 post-treatment and was counted towards achieving SVR.</p